Thomas Knittel

Title: Innovations of Thomas Knittel in the Field of Inflammatory Bowel Disease

Introduction

Thomas Knittel is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of medical research, particularly in the treatment of inflammatory bowel disease. With a total of 2 patents, his work is recognized for its innovative approach to therapy.

Latest Patents

Among his latest patents, one invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3' (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject. This invention specifies that individual doses ranging from 100 mg to 350 mg of the oligonucleotide are to be administered to the subject on at least four separate occasions, with each occasion spaced a week apart. Another significant patent focuses on Cobitolimod for the treatment of inflammatory bowel disease, detailing the administration of doses between 150 mg and 350 mg on at least two separate occasions, with those occasions occurring three weeks apart.

Career Highlights

Thomas Knittel is currently associated with Index Pharmaceuticals AB, where he continues to advance his research and innovations. His work has been pivotal in developing new therapeutic options for patients suffering from inflammatory bowel disease.

Collaborations

He collaborates with talented individuals such as Arezou Zargari and Charlotte Admyre, contributing to a dynamic research environment that fosters innovation.

Conclusion

Thomas Knittel's contributions to the field of inflammatory bowel disease through his patents and collaborations highlight his role as a significant inventor in medical research. His innovative approaches are paving the way for new treatment options that can improve patient outcomes.